Impact Biomedicines

Impact Biomedicines is developing life-changing treatments for cancer patients. The company’s pipeline centers on fedratinib, an effective and highly selective oral small molecule JAK2 kinase inhibitor, initially targeting myelofibrosis and polycythemia vera.